P-208 - EXPOSURE RESPONSE ANALYSES OF NIVOLUMAB AS ADJUVANT TREATMENT FOR PATIENTS WITH ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER (CHECKMATE 577).
Y. Zhao1, A. Tsujimoto2, T. Ide1, L. Zhu1, J. Zhang1, Y. Feng1, L. Gao1; 1Bristol Myers Squibb, Princeton, NJ, USA, 2Bristol Myers Squibb, Shinjuku, Tokyo.
.png)